Abstract:Neoantigens, presented as peptides on the surfaces of cancer cells, have recently been proposed as optimal targets for immunotherapy in clinical practice. The promising outcomes of neoantigen-based cancer vaccines have inspired enthusiasm for their broader clinical applications. However, the individualized tumor-specific antigens (TSA) entail considerable costs and time due to the variable immunogenicity and response rates of these neoantigens-based vaccines, influenced by factors such as neoantigen response, vaccine types, and combination therapy. Given the crucial role of neoantigen efficacy, a number of bioinformatics algorithms and pipelines have been developed to improve the accuracy rate of prediction through considering a series of factors involving in HLA-peptide-TCR complex formation, including peptide presentation, HLA-peptide affinity, and TCR recognition. On the other hand, shared neoantigens, originating from driver mutations at hot mutation spots (e.g., KRASG12D), offer a promising and ideal target for the development of therapeutic cancer vaccines. A series of clinical practices have established the efficacy of these vaccines in patients with distinct HLA haplotypes. Moreover, increasing evidence demonstrated that a combination of tumor associated antigens (TAAs) and neoantigens can also improve the prognosis, thus expand the repertoire of shared neoantigens for cancer vaccines. In this review, we provide an overview of the complex process involved in identifying personalized neoantigens, their clinical applications, advances in vaccine technology, and explore the therapeutic potential of shared neoantigen strategies.

Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy

Circular RNA-based neoantigen vaccine for hepatocellular carcinoma immunotherapy

Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies

Circular RNAs in tumor immunity and immunotherapy

The emerging prospects of circular RNA in tumor immunity

Neoantigens: promising targets for cancer therapy

Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact

Recent advances of neoantigen in tumor therapy

Synergically enhanced anti-tumor immunity of in vivo CAR by circRNA vaccine boosting

CircRNAs in tumor immunity and immunotherapy: Perspectives from innate and adaptive immunity

Personalized Neoantigen Vaccination with Synthetic Long Peptides: Recent Advances and Future Perspectives

Nanomaterial Delivery Vehicles for the Development of Neoantigen Tumor Vaccines for Personalized Treatment

Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy

Circular RNA: A promising new star of vaccine

Neoantigen: A New Breakthrough in Tumor Immunotherapy

Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapy

Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity

Advances and applications of RNA vaccines in tumor treatment

Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens

Development and Clinical Applications of Therapeutic Cancer Vaccines with Individualized and Shared Neoantigens

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy